Loading news...
The average of price targets set by Wall Street analysts indicates a potential upside of 230.6% in Assertio (ASRT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The consensus price target hints at a 249.9% upside potential for Assertio (ASRT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here is how Assertio (ASRT) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Assertio Holdings, Inc. (NASDAQ: ASRT - Get Free Report) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 285,110 shares, a decrease of 92.8% from the December 15th total of 3,935,645 shares. Approximately 4.6% of the company's shares are short sold.
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with all applicable listing requirements. As of January 12, 2026, Nasdaq has determined that Assertio has regained compliance with the Minimum Bid Price Rule, which requires the Company's common stock maintains a minimum bid price of $1.00 per share for a min.
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon® (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an e.
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the “Certificate of Amendment”) on December 19 to implement a one-for-fifteen reverse split of its issued and outstanding common stock (the “Reverse Split”). The Reverse Split will become effective as of 12:01 a.m. Eastern Time on December 26, 2025, and the Company's common stock will begin trading.
Assertio (ASRT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.03 per share a year ago.
Assertio Holdings, Inc. ( ASRT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Mark L. Reisenauer - CEO & Director Paul Schwichtenberg - Executive VP & Chief Transformation Officer Ajay Patel - Executive VP & CFO Conference Call Participants Daniel Santos Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Nazibur Rahman - Maxim Group LLC, Research Division Raghuram Selvaraju - H.C.
LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today reported financial results for the third quarter ended September 30, 2025. Mark Reisenauer, Chief Executive Officer, stated: “In the third quarter we achieved financial results that position us to achieve our full-year 2025 guidance. We also advance.
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill.
SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
PHILADELPHIA , Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period").
ATS, ASRT and DBVT have been added to the Zacks Rank #5 (Strong Sell) List on September 23, 2025.
SAN FRANCISCO, Sept. 21, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
SAN FRANCISCO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.
ASRT, CE and ARR have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2025.
PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).
ASRT, ARMN and AMRZ have been added to the Zacks Rank #5 (Strong Sell) List on September 16, 2025.
BALTIMORE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today announced new data from a first-ever real-world study of SYMPAZAN (clobazam) Oral Film.